Bristol-Myers Squibb's $74 billion acquisition of rival drugmaker Celgene Corp., and its goal to cut $2.5 billion in costs from the joint entity, is raising questions about how the consolidation will affect Celgene's headquarters as well as its large research and development campus in Summit, New Jersey.
Watch the video to learn how you can access industry leading CRE news and the data analytics you need to drive success.
This news story is available exclusively to CoStar subscribers.
Ready to Learn More?
Sign Up For a Personalized Demo.
Sign Up For a Demo To Learn More.
Already A Subscriber? Sign In
86 Morris Ave, Summit, NJ
86 Morris Ave, Summit, NJ
556 Morris Ave, Summit, NJ